Skip to main content
SpringerLink
Log in

CML with e6a2 BCR-ABL1 transcript: an aggressive entity?

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Schnittger S, Bacher U, Kern W, Haferlach T, Hertenstein B, Haferlach C (2008) A new case with rare e6a2 BCR-ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment. Leukemia 22(4):856–858

    Article  PubMed  CAS  Google Scholar 

  2. Torres F, Ivanova-Dragoeva A, Pereira M, Veiga J, Rodrigues AS, Sousa AB, Tavares P, Fernandes AR (2007) An e6a2 BCR-ABL fusion transcript in a CML patient having an iliac chloroma at initial presentation. Leuk Lymphoma 48(5):1034–1037

    Article  PubMed  CAS  Google Scholar 

  3. Colla S, Sammarelli G, Voltolini S, Crugnola M, Sebastio P, Giuliani N (2004) e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease? Haematologica 89(5):611–613

    PubMed  Google Scholar 

  4. Hochhaus A, Reiter A, Skladny H, Melo JV, Sick C, Berger U, Guo JQ, Arlinghaus RB, Hehlmann R, Goldman JM, Cross NC (1996) A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia. Blood 88(6):2236–2240

    PubMed  CAS  Google Scholar 

  5. Dupont M, Jourdan E, Chiesa J (2000) Identification of E6A2 BCR-ABL fusion in a Philadelphia-positive CML. Leukemia 14(11):2011–2012

    Article  PubMed  CAS  Google Scholar 

  6. Schultheis B, Wang L, Clark RE, Melo JV (2003) BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis. Leukemia 17(10):2054–2055

    Article  PubMed  CAS  Google Scholar 

  7. Roti G, La Starza R, Gorello P, Gottardi E, Crescenzi B, Martelli MF, Mecucci C (2005) e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia. Haematologica 90(8):1139–1141

    PubMed  Google Scholar 

  8. Popovici C, Cailleres S, David M, Lafage-Pochitaloff M, Sainty D, Mozziconacci MJ (2005) E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to Imatinib. Leuk Lymphoma 46(9):1375–1377

    Article  PubMed  CAS  Google Scholar 

  9. Breccia M, Cannella L, Diverio D, Streponi P, Nanni M, Stefanizzi C, Natalino F, Mecarocci S, Alimena G (2008) Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinib. Leuk Res 32(1):177–180

    Article  PubMed  CAS  Google Scholar 

  10. Vefring HK, Gruber FX, Wee L, Hovland R, Hjorth-Hansen H, Gedde Dahl T, Meyer P (2009) Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases. Acta Haematol 122(1):11–16

    Article  PubMed  Google Scholar 

  11. Langabeer SE, Crampe M, Kelly J, Fadalla K, Connaghan G, Conneally E (2010) Nilotinib and allogeneic stem cell transplantation in a chronic myeloid leukemia patient with e6a2 and e1a2 BCR-ABL transcripts. Leuk Res 34(8):e204–e205

    Article  PubMed  Google Scholar 

  12. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, Gottardi E, Rambaldi A, Dotti G, Griesinger F, Parreira A, Gameiro P, Diaz MG, Malec M, Langerak AW, San Miguel JF, Biondi A (1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 13(12):1901–1928

    Article  PubMed  Google Scholar 

  13. Valent P, Lion T, Wolf D, Sillaber C, Agis H, Petzer A, Lang A, Kahls P, Geissler D, Greil R, Linkesch W, Burgstaller S, Thaler J, Gastl G (2008) Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform. Wien Klin Wochenschr 120(21–22):697–709

    Article  PubMed  CAS  Google Scholar 

  14. Cross NC, Melo JV, Feng L, Goldman JM (1994) An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 8(1):186–189

    PubMed  CAS  Google Scholar 

  15. Jinawath N, Norris-Kirby A, Smith BD, Gocke CD, Batista DA, Griffin CA, Murphy KM (2009) A rare e14a3 (b3a3) BCR-ABL fusion transcript in chronic myeloid leukemia. Diagnostic challenges in clinical laboratory practice. J Mol Diagn 11(4):359–363

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Internal Medicine, University Hospital Leuven, Leuven, Belgium

    Karolien Anne Beel & Johan Maertens

  2. Department of Hematology, GZA-ziekenhuizen, Wilrijk, Belgium

    Jan Lemmens

  3. Center for Human Genetics, University Hospitals Leuven, Leuven, Belgium

    Hilde Vranckx & Peter Vandenberghe

Authors
  1. Karolien Anne Beel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jan Lemmens
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hilde Vranckx
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Johan Maertens
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peter Vandenberghe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Vandenberghe.

Additional information

PV is a senior clinical investigator of the Fund for Scientific Research-Flanders (Belgium) (FWO Vlaanderen).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beel, K.A., Lemmens, J., Vranckx, H. et al. CML with e6a2 BCR-ABL1 transcript: an aggressive entity?. Ann Hematol 90, 1241–1243 (2011). https://doi.org/10.1007/s00277-011-1169-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-011-1169-4

Keywords

Search

Navigation